Evaluation of clinical usefulness of a novel pancreatic cancer marker

Not Applicable

Recruiting

• Conditions: Pancreatic cancer

• Registration Number: JPRN-UMIN000040990
• Lead Sponsor: Yokohama City University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-06
• Last Update Posted: 17 October 2023
• Study Completion: 2025-03-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with simultaneous or metachronous double cancer. 2.Samples taken from patients who is considered inappropriate for the inclusion by the responsible physician of each institution. 3. Patients who are pregnant or may be pregnant at the time of blood collection.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the clinical diagnostic performance of TFPI2 in patients with pancreatic cancer (diagnostic accuracy, sensitivity, sensitivity, ROC curve analysis, area under the ROC curve)

Secondary Outcome Measures

Name	Time	Method
To evaluate the complementarity between TFPI2 and conventional markers (CEA, CA19-9, DUPAN-2, SPAN-1). To investigate relation between TFPI2 and thrombosis (D-dimer or imge findings).